Benefit of pegylated interferon-alpha-2a/ribavirin in a patient with common variable immunodeficiency and hepatitis C virus cirrhosis after liver transplantation and splenic embolization

Transplantation. 2006 Jul 27;82(2):289-90. doi: 10.1097/01.tp.0000226223.95971.e7.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antiviral Agents / therapeutic use
  • Hepatitis C / drug therapy*
  • Hepatitis C / surgery*
  • Humans
  • Immunoglobulin G / therapeutic use
  • Immunologic Deficiency Syndromes / drug therapy*
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use*
  • Liver Transplantation / immunology*
  • Male
  • Polyethylene Glycols / therapeutic use*
  • Recombinant Proteins
  • Ribavirin / therapeutic use*
  • Treatment Outcome
  • Viral Load

Substances

  • Antiviral Agents
  • Immunoglobulin G
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • peginterferon alfa-2a